Literature DB >> 15649255

Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation.

Hitoshi Tsuda1, Daisaku Morita, Mikihiko Kimura, Eiji Shinto, Yukiko Ohtsuka, Osamu Matsubara, Johji Inazawa, Kuniyoshi Tamaki, Hidetaka Mochizuki, Seiichi Tamai, Hoshio Hiraide.   

Abstract

Although KIT and EGFR overexpressions are reported to occur in breast cancer, their pathological significance is still unclear. We examined KIT, EGFR, and c-erbB-2 overexpressions immunohistochemically in 150 cases of surgically resected breast cancer and their correlation with the histological type and grade and mesenchymal and/or myoepithelial immunophenotype of primary tumors. To facilitate the analysis, we constructed a tissue microarray comprising 2-mm diameter tissues cored from the representative tissue block of each tumor. KIT, EGFR, and c-erbB-2 overexpressions were detected in 15 (10%), 12 (8%), and 23 (15%), respectively. The KIT was more frequent in the group comprising comedo-type ductal carcinoma in situ and invasive ductal carcinomas (IDCs) of the solid-tubular subtype than in the group of other histological types (P=0.027), and the EGFR was more frequent in IDCs of solid-tubular type than in other histological types (P <0.05). KIT and EGFR overexpressions were correlated with nuclear grade 3 (P=0.0095 and 0.0005) and tended to be concurrent (P=0.005). KIT overexpression was correlated with vimentin and S-100 expression (P=0.003 and P=0.005), and EGFR overexpression was correlated with S100 expression (P=0.0001). These correlations with grade and mesenchymal/myoepithelial markers were not observed for c-erbB-2 overexpression. KIT and EGFR appeared to be indicators of high-grade breast carcinoma groups that often contain the carcinomas with mesenchymal and/or myoepithelial differentiation, which are distinct from the group with c-erbB-2 overexpression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15649255     DOI: 10.1111/j.1349-7006.2005.00009.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  21 in total

1.  Screening of the c-kit gene missense mutation in invasive ductal carcinoma of breast among north Indian population.

Authors:  Syed Rizwan Hussain; Sunil G Babu; Syed Tasleem Raza; Pradyumn Singh; Faisal Ahmed; Hena Naqvi; Farzana Mahdi
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

2.  The current understanding of the molecular determinants of inflammatory breast cancer metastasis.

Authors:  Galina S Radunsky; Kenneth L van Golen
Journal:  Clin Exp Metastasis       Date:  2006-04-27       Impact factor: 5.150

3.  Triple-Negative Breast Cancer: Clinical and Histological Correlations.

Authors:  Zeinab Elsawaf; Hans-Peter Sinn
Journal:  Breast Care (Basel)       Date:  2011-08-26       Impact factor: 2.860

4.  Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.

Authors:  Donna S Dorow; Carleen Cullinane; Nelly Conus; Peter Roselt; David Binns; Timothy J McCarthy; Grant A McArthur; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-01       Impact factor: 9.236

5.  Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.

Authors:  Socorro María Rodríguez-Pinilla; David Sarrió; Emiliano Honrado; Gema Moreno-Bueno; David Hardisson; Francisco Calero; Javier Benítez; José Palacios
Journal:  J Clin Pathol       Date:  2006-11-14       Impact factor: 3.411

6.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.

Authors:  Helen K Chew; William E Barlow; Kathy Albain; Danika Lew; Allen Gown; Daniel F Hayes; Julie Gralow; Gabriel N Hortobagyi; Robert Livingston
Journal:  Clin Breast Cancer       Date:  2008-12       Impact factor: 3.225

7.  The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma.

Authors:  Naoto Kuroda; Masahiko Ohara; Kaori Inoue; Keiko Mizuno; Nokiaki Fujishima; Nobumasa Hamaguchi; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2009-06-18       Impact factor: 2.309

8.  Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas.

Authors:  Naoto Kuroda; Nokiaki Fujishima; Kaori Inoue; Masahiko Ohara; Takashi Hirouchi; Keiko Mizuno; Yoshihiro Hayashi; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2008-07-01       Impact factor: 2.309

9.  Determination of whole transcription profiles and specific pathways in invasive ductal breast carcinoma.

Authors:  Pasra Arnutti; Manas Kotepui; Wichitra Asanprakit; Phaibul Punyarit; Porntip Chavalitshewinkoon-Petmitr; Talabporn Harnroongroj; Songsak Petmitr
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

10.  Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome.

Authors:  C Charpin; S Giusiano; S Charfi; V Secq; S Carpentier; L Andrac; M-N Lavaut; C Allasia; P Bonnier; S Garcia
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.